Tag: Microgen

Microgen – Russian pharmaceutical company.

Federal State Scientific-Industrial Company MICROGEN is the largest company in Russian medical industry that holds leadership in development and production of immunobiological preparations, diagnosticums and drugs.

Consortium MICROGEN was founded in May, 2003 in order to create a competitive enterprise in the field of medical immunobiology that could ensure the implementation of national programs of biological and epidemiological security, development of domestic biotechnological industry in accordance with international standards of drug production and practical application of new and highly effective preparations.

Subsidiaries that were amalgamated within the MICROGEN have a history that is more than a hundred years long. They were created on the basis of Pasteur centers and laboratories that conducted studies in the field of immunobiology.

At present Federal State Scientific-Industrial Company MICROGEN is a modern enterprise that holds leadership position in the domestic pharmaceutical industry. Production output for MICROGEN in the year 2013 was more than US$150m.

The company steadily widens the shipping geography of its immunobiological products: they go to the CIS countries (Kazakhstan, Ukraine, Byelorussia, Uzbekistan, Azerbaijan, Armenia, Georgia), Mexico, Mongolia, Vietnam, India. A number of countries of Africa, South-East Asia and Latin America are conducting talks concerning future cooperation.

MICROGEN Consortium in active cooperation with leading Russian and foreign research centers is working on designing and application to production development of the unique innovations in immunobiology and biotechnology.

In collaboration with leading Russian scientists the company is striving to develop and manufacture new high-quality preparations, modern pharmaceutical forms.

MICROGEN specialists participate in international research projects including WHO programs for eradication of natural smallpox, measles, rubella, tuberculosis, whooping cough, diphtheria, tetanus, avian flu, etc.

At present more than 15 novel preparations are being prepared for commercial production, e.g. new influenza, smallpox and tick-borne encephalitis vaccines, associated DTP vaccine, hepatitis B vaccine, hemophilic infection vaccine, mumps, measles and rubella vaccine, avian flu vaccine, cell-depleted pertussis vaccine, staphylococcal-proteus-pseudomonas aeruginosa vaccine (SPPA-vaccine) and others.

NPO Microgen launches a production area for botulinum toxins

NPO Microgen, a subsidiary of Nacimbio holding company of Rostec Corporation, is launching a new modern production area to manufacture Relatox, the only Russian botulinum toxin type A

Rostec starts digital labeling of medicinal products manufactured at its plants

As part of the drug labeling project, NPO Microgen of Nacimbio holding company, a part of Rostec Corporation, has completed the initial pilot stage

NPO Microgen cerebral palsy drug is in no way inferior to foreign analogs

NPO Microgen has completed the clinical trials of the first Russian botulinum toxin-based drug for the treatment of spastic forms of cerebral palsy

Nacimbio presents its key projects and new R&D

Nacimbio, a pharmaceutical holding company of Rostec Corporation, takes part in PharmMedProm-2017 exhibition held during the Russian Health Care Week

Microgen receives a 1.5 billion ruble loan

Novikombank will provide a 1.5 billion ruble loan for a period of three years to NPO Microgen, a part of Nacimbio Holding Company of Rostec Corporation

Vaccination will become a driver of economic growth in the 21st century

Nikolai Briko, Doctor of Medical Sciences and Member of the Scientific and Technical Council of Nacimbio, said that this century is the age of vaccines

Nacimbio completes trials of pentavaccine with acellular pertussis component

National Immunobiological Company (Nacimbio) completed the clinical trials of the first Russian combined 5-component vaccine with acellular pertussis component

Nacimbio presents its new products at the international conference

Nacimbio presented to the scientific community the results of the study of epidemiological efficacy of the flu vaccines manufactured by the enterprises of the holding company.

Transition to multicomponent preventive drugs is necessary

influenza vaccine
During the second BIOTECHMED conference, the representatives of Nacimbio participated in panel discussions on preventive vaccination and expansion of the National Immunization Calendar

Microgen was the first to confirm genetic stability of Russian vaccine

mikrogen vaccine
NPO Microgen was the first among the Russian manufacturers to confirm the stability of the vaccine virus strain and the quality of manufacturing of Russian-made tick-borne encephalitis vaccines at the gene level in accordance with WHO recommendations

NPO Microgen strengthens its control over manufacturing of TB vaccines

For the first time in Russia the Scientific and Production Association “Microgen”, a part of Nacimbio holding company, has implemented the control over the manufacturing of TB vaccines

New technology will make vaccines quality control in Russia 300 times faster

National Immunobiological Company (Nacimbio) introduces a new technology to control the quality of anti-TB vaccines that cuts the period of procedure from one month to 1.5 hours. The technology is dev...

Russian botulinum toxin confirmed its compliance with quality requirements

Relatox, the first and only one Russian-made botulinum toxin manufactured by Nacimbio holding company, a part of Rostec Corporation confirmed its compliance with the requirements of the state expert e...

Nacimbio produce more than 70% of required immunization medicines

National Immunobiological Company presented its immunobiological products at all-Russian forum and exhibition "State Order – For Fair Procurement". Nacimbio plants produce more than 70% of the volume ...

Nacimbio starts clinical trials of the first Russian meningococcal vaccine

clinical trial
NPO Microgen, part of the National Immunobiological Company, has begun Phase I clinical trials of the first Russian polysaccharide meningococcal vaccine against serotypes A and C. The preclinical stud...

Microgen is ready to market a unique bacteriophage

Combined bacteriophage preparation "Enterobacter multivalent purified" intended for treatment and prevention of infections caused by Enterobacter species has successfully passed the phase II clinical ...